P-glycoprotein activity in the blood-brain barrier is affected by virus-induced neuroinflammation and antipsychotic treatment

Neuropharmacology

Volumn 85, Issue , 2014, Pages 548-553

  Doorduin, Janine ^a   De Vries, Erik F J ^a   Dierckx, Rudi A ^a   Klein, Hans C ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Antipsychotics; Herpes simplex virus; Neuroinflammation; P glycoprotein; Positron emission tomography

Indexed keywords

CARBON 11; CLOZAPINE; MULTIDRUG RESISTANCE PROTEIN; RISPERIDONE; VERAPAMIL; CARBON; NEUROLEPTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CEREBELLUM; CONTROLLED STUDY; CORPUS STRIATUM; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; FRONTAL CORTEX; HERPES SIMPLEX ENCEPHALITIS; HERPES SIMPLEX VIRUS 1; MALE; MESENCEPHALON; MOTOR DYSFUNCTION; NONHUMAN; OCCIPITAL CORTEX; OLFACTORY BULB; PARIETAL CORTEX; PLASMA CONCENTRATION-TIME CURVE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN FUNCTION; PSYCHIATRIC TREATMENT; RAT; SCHIZOPHRENIA; SCORING SYSTEM; TEMPORAL CORTEX; THALAMUS; ANIMAL; BRAIN; COMPARATIVE STUDY; DIAGNOSTIC USE; DISEASE MODEL; DRUG EFFECTS; HERPES SIMPLEX; IMMUNOLOGY; IMMUNOMODULATION; METABOLISM; PHYSIOLOGY; RANDOMIZATION; SCINTISCANNING; WISTAR RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; BLOOD-BRAIN BARRIER; BRAIN; CARBON RADIOISOTOPES; CLOZAPINE; DISEASE MODELS, ANIMAL; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; MALE; NEUROIMMUNOMODULATION; P-GLYCOPROTEINS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RANDOM ALLOCATION; RATS, WISTAR; RISPERIDONE; VERAPAMIL;

EID: 84903948739     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2014.06.017     Document Type: Article

References (41)

1. R.N. Aravalli, S. Hu, T.N. Rowen, J.M. Palmquist, and J.R. Lokensgard Cutting edge: TLR2-mediated proinflammatory cytokine and chemokine production by microglial cells in response to herpes simplex virus J. Immunol. 175 7 2005 Oct 1 4189 4193 Available from: http://www.ncbi.nlm.nih.gov/pubmed/16177057 (Pubitemid 41361951)
2. A. Attard, and D.M. Taylor Comparative effectiveness of atypical antipsychotics in schizophrenia: what have real-world trials taught us? CNS Drugs 26 6 2012 Jun 1 491 508 Available from: http://www.ncbi.nlm.nih.gov/ pubmed/22668246
3. R.J. Baldessarini, F. Centorrino, J.G. Flood, S.A. Volpicelli, D. Huston-Lyons, and B.M. Cohen Tissue concentrations of clozapine and its metabolites in the rat Neuropsychopharmacology 9 2 1993 Sep 117 124 Available from: http://www.ncbi.nlm.nih.gov/pubmed/8216694 (Pubitemid 23275837)
4. B. Bauer, A.M.S. Hartz, and D.S. Miller Tumor necrosis factor alpha and endothelin-1 increase P-glycoprotein expression and transport activity at the blood-brain barrier Mol. Pharmacol. 71 3 2007 Mar 667 675 Available from: http://www.ncbi.nlm.nih.gov/pubmed/17132686 (Pubitemid 46294078)
5. D.W. Boulton, C.L. DeVane, H.L. Liston, and J.S. Markowitz In vitro P-glycoprotein affinity for atypical and conventional antipsychotics Life Sci. 71 2 2002 May 31 163 169 Available from: http://www.ncbi.nlm.nih.gov/pubmed/ 12031686 (Pubitemid 34595435)
6. N. Bozina, M.R. Kuzman, V. Medved, N. Jovanovic, J. Sertic, and L. Hotujac Associations between MDR1 gene polymorphisms and schizophrenia and therapeutic response to olanzapine in female schizophrenic patients J. Psychiatr. Res. 42 2 2008 Jan 89 97 Available from: http://www.ncbi.nlm.nih.gov/ pubmed/17113599 (Pubitemid 350061252)
7. APW de Castro, and H. Elkis Rehospitalization rates of patients with schizophrenia discharged on haloperidol, risperidone or clozapine Rev. Bras. Psiquiatr. 29 3 2007 Sep 207 212 Available from: http://www.ncbi.nlm.nih.gov/ pubmed/17891257
8. R.R. Conley, and R.W. Buchanan Evaluation of treatment-resistant schizophrenia Schizophr. Bull. 23 4 1997 Jan 663 674 Available from: http://www.ncbi.nlm.nih.gov/pubmed/9366002 (Pubitemid 27485974)
9. O.L. De Klerk, A.T.M. Willemsen, F.J. Bosker, A.L. Bartels, N.H. Hendrikse, and J a den Boer et al. Regional increase in P-glycoprotein function in the blood-brain barrier of patients with chronic schizophrenia: a PET study with [(11)C]verapamil as a probe for P-glycoprotein function Psychiatry Res. 183 2 2010 Aug 30 151 156 Elsevier Ireland Ltd. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20620031
10. J. Doorduin, E.F.J. de Vries, A.T.M. Willemsen, J.C. de Groot, R.A. Dierckx, and H.C. Klein Neuroinflammation in schizophrenia-related psychosis: a PET study J. Nucl. Med. 50 11 2009 Nov 1801 1807 Available from: http://www.ncbi.nlm.nih.gov/pubmed/19837763
11. M. Dossenbach, J. Pecenak, A. Szulc, V. Irimia, M. Anders, and D. Logozar-Perkovic et al. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study J. Clin. Psychiatry 69 12 2008 Dec 1901 1915 Available from: http://www.ncbi.nlm.nih.gov/pubmed/19012820
12. R.C. Drexhage, L. van der Heul-Nieuwenhuijsen, R.C. Padmos, N. van Beveren, D. Cohen, and M.A. Versnel et al. Inflammatory gene expression in monocytes of patients with schizophrenia: overlap and difference with bipolar disorder. A study in naturalistically treated patients Int. J. Neuropsychopharmacol. 13 10 2010 Nov 1369 1381 Available from: http://www.ncbi.nlm.nih.gov/pubmed/20633309
13. R.C. Drexhage, T.A. Hoogenboezem, D. Cohen, M.A. Versnel, W.A. Nolen, and N.J.M. van Beveren et al. An activated set point of T-cell and monocyte inflammatory networks in recent-onset schizophrenia patients involves both pro- and anti-inflammatory forces Int. J. Neuropsychopharmacol. 14 6 2011 Jul 746 755 Available from: http://www.ncbi.nlm.nih.gov/pubmed/21255481
14. A.A. El Ela, S. Härtter, U. Schmitt, C. Hiemke, H. Spahn-Langguth, and P. Langguth Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds-implications for pharmacokinetics of selected substrates J. Pharm. Pharmacol. 56 8 2004 Aug 967 975 Available from: http://www.ncbi.nlm. nih.gov/pubmed/15285840 (Pubitemid 39140051)
15. M.A. Geyer, K. Krebs-Thomson, D.L. Braff, and N.R. Swerdlow Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review Psychopharmacology 2001 Available from: http://link.springer.com/10.1007/s002130100811
16. K.B. Goralski, G. Hartmann, M. Piquette-Miller, and K.W. Renton Downregulation of mdr1a expression in the brain and liver during CNS inflammation alters the in vivo disposition of digoxin Br. J. Pharmacol. 139 1 2003 May 35 48 Available from: http://www.pubmedcentral.nih.gov/articlerender. fcgi?artid=1573825&tool=pmcentrez&rendertype=abstract (Pubitemid 36645306)
17. A. Hartz, B. Bauer, G. Fricker, and D. Miller Rapid regulation of P-glycoprotein at the blood-brain barrier by endothelin-1 Mol. Pharmacol. 66 3 2004 387 394 Available from: http://molpharm.aspetjournals.org/content/66/3/387. short (Pubitemid 39329237)
18. A. Hartz, B. Bauer, G. Fricker, and D. Miller Rapid modulation of P-glycoprotein-mediated transport at the blood-brain barrier by tumor necrosis factor-alpha and lipopolysaccharide Mol. Pharmacol. 69 2 2006 462 470 Available from: http://molpharm.aspetjournals.org/content/69/2/462.short (Pubitemid 43121943)
19. F. Imbert, M. Jardin, C. Fernandez, J.C. Gantier, F. Dromer, and G. Baron et al. Effect of efflux inhibition on brain uptake of itraconazole in mice infected with Cryptococcus neoformans Drug Metab. Dispos. 31 3 2003 Mar 319 325 Available from: http://www.ncbi.nlm.nih.gov/pubmed/12584159 (Pubitemid 36249687)
20. S. Kapur, S.C. Vanderspek, B.A. Brownlee, and E. Jos Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a Suggested solution based on in vivo occupancy Pharmacology 305 2 2003 625 631 (Pubitemid 36459179)
21. J. Lieberman, D. Jody, S. Geisler, J. Alvir, A. Loebel, and S. Szymanski et al. Time course and biologic correlates of treatment response in first-episode schizophrenia Arch. Gen. Psychiatry 50 5 1993 May 369 376 Available from: http://www.ncbi.nlm.nih.gov/pubmed/8098203 (Pubitemid 23143126)
22. J. Logan Graphical analysis of PET data applied to reversible and irreversible tracers Nucl. Med. Biol. 27 7 2000 Oct 661 670 Available from: http://www.ncbi.nlm.nih.gov/pubmed/11091109
23. W. Löscher, and H. Potschka Drug resistance in brain diseases and the role of drug efflux transporters Nat. Rev. Neurosci. 6 8 2005 Aug 591 602 Available from: http://www.ncbi.nlm.nih.gov/pubmed/16025095 (Pubitemid 41059334)
24. J. McGrath, S. Saha, D. Chant, and J. Welham Schizophrenia: a concise overview of incidence, prevalence, and mortality Epidemiol. Rev. 30 2008 Jan 67 76 Available from: http://www.ncbi.nlm.nih.gov/pubmed/18480098
25. D.S. Miller Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier Trends Pharmacol. Sci. 31 6 2010 Jun 246 254 Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid= 2882496&tool=pmcentrez&rendertype=abstract
26. M. Minami, M. Kita, X.-Q. Yan, T. Yamamoto, T. Iida, and K. Sekikawa et al. Role of IFN-gamma and tumor necrosis factor-alpha in herpes simplex virus type 1 infection J. Interferon Cytokine Res. 22 6 2002 Jun 671 676 Available from: http://www.ncbi.nlm.nih.gov/pubmed/12162877 (Pubitemid 35034525)
27. D.J. Roberts, and K.B. Goralski A critical overview of the influence of inflammation and infection on P-glycoprotein expression and activity in the brain Expert Opin. Drug Metab. Toxicol. 4 10 2008 Oct 1245 1264 Available from: http://www.ncbi.nlm.nih.gov/pubmed/18798696
28. U. Schmitt, K.M. Kirschbaum, B. Poller, M. Kusch-Poddar, J. Drewe, and C. Hiemke et al. In vitro P-glycoprotein efflux inhibition by atypical antipsychotics is in vivo nicely reflected by pharmacodynamic but less by pharmacokinetic changes Pharmacol. Biochem. Behav. 102 2 2012 Aug 312 320 Elsevier Inc. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22525746
29. T. Suzuki, G. Remington, B.H. Mulsant, T.K. Rajji, H. Uchida, and A. Graff-Guerrero et al. Treatment resistant schizophrenia and response to antipsychotics: a review Schizophr. Res. 133 1-3 2011 Dec 54 62 Elsevier B.V. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22000940
30. T. Takao, H. Tachikawa, Y. Kawanishi, T. Katano, B. Sen, and M. Homma et al. Association of treatment-resistant schizophrenia with the G2677A/T and C3435T polymorphisms in the ATP-binding cassette subfamily B member 1 gene Psychiatr. Genet. 16 2 2006 May 47 48 Available from: http://www.ncbi.nlm.nih. gov/pubmed/16538177 (Pubitemid 44481201)
31. R. Tandon, H.A. Nasrallah, and M.S. Keshavan Schizophrenia, "just the facts" 4. Clinical features and conceptualization Schizophr. Res. 110 1-3 2009 May 1 23 Elsevier B.V. Available from: http://www.ncbi.nlm.nih.gov/ pubmed/19328655
32. L.E. Van Beijsterveldt, R.J. Geerts, J.E. Leysen, A.A. Megens, H.M. Van den Eynde, and W.E. Meuldermans et al. Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat Psychopharmacology (Berl) 114 1 1994 Feb 53 62 Available from: http://www.ncbi.nlm.nih.gov/pubmed/7531352 (Pubitemid 24150520)
33. B.N. Van Berckel, M.G. Bossong, R. Boellaard, R. Kloet, A. Schuitemaker, and E. Caspers et al. Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study Biol. Psychiatry 64 9 2008 Nov 1 820 822 Available from: http://www.ncbi.nlm.nih.gov/ pubmed/18534557
34. K. Wahlbeck, M. Cheine, A. Essali, and C. Adams Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials Am. J. Psychiatry 156 7 1999 Jul 990 999 Available from: http://www.ncbi.nlm.nih.gov/pubmed/10401441 (Pubitemid 29302789)
35. J. Wang, D.A. Scollard, S. Teng, R.M. Reilly, and M. Piquette-Miller Detection of P-glycoprotein activity in endotoxemic rats by 99mTc-sestamibi imaging J. Nucl. Med. 46 9 2005 Sep 1537 1545 Available from: http://www.ncbi.nlm.nih.gov/pubmed/16157538 (Pubitemid 46173265)
36. J.-S. Wang, H.-J. Zhu, J.S. Markowitz, J.L. Donovan, and C.L. DeVane Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein Psychopharmacology (Berl) 187 4 2006 Sep 415 423 Available from: http://www.ncbi.nlm.nih.gov/pubmed/16810505 (Pubitemid 44200513)
37. 11C]verapamil Appl. Radiat. Isot. 57 4 2002 Oct 505 507 Available from: http://www.ncbi.nlm.nih.gov/pubmed/12361330
38. C. Yu, A.J. Kastin, H. Tu, S. Waters, and W. Pan TNF activates P-glycoprotein in cerebral microvascular endothelial cells Cell Physiol. Biochem. 20 6 2007 Jan 853 858 Available from: http://www.ncbi.nlm.nih.gov/ pubmed/17982267 (Pubitemid 350059728)
39. C. Yu, G. Argyropoulos, Y. Zhang, A.J. Kastin, H. Hsuchou, and W. Pan Neuroinflammation activates Mdr1b efflux transport through NFkappaB: promoter analysis in BBB endothelia Cell Physiol. Biochem. 22 5-6 2008 Jan 745 756 Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid= 2677694&tool=pmcentrez&rendertype=abstract
40. Y.L. Zhao, J. Du, H. Kanazawa, A. Sugawara, K. Takagi, and K. Kitaichi et al. Effect of endotoxin on doxorubicin transport across blood-brain barrier and P-glycoprotein function in mice Eur. J. Pharmacol. 445 1-2 2002 Jun 7 115 123 Available from: http://www.ncbi.nlm.nih.gov/pubmed/12065202 (Pubitemid 34628440)
41. H.-J. Zhu, J.-S. Wang, J.S. Markowitz, J.L. Donovan, B.B. Gibson, and C.L. DeVane Risperidone and paliperidone inhibit p-glycoprotein activity in vitro Neuropsychopharmacology 32 4 2007 Apr 757 764 Available from: http://www.ncbi.nlm.nih.gov/pubmed/16936711 (Pubitemid 46426181)